ArticleBritish journal of cancer2010

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.

P Schöffski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.